Detection of serum soluble B7-H4 in patients with non-metastatic clear cell renal cell carcinoma.

<p>The concentration of the soluble B7-H4 in the HDs and the patients diagnosed with renal cell carcinoma. Sera from 108 renal cancer patients and 108 HDs were diluted 1:10 in PBS and tested by ELISA as described in <a href="http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000166#s2" target="_blank">Materials and Methods</a>. The data were analyzed using the Mann-Whitney U test followed by multiple regression analysis (<i>p</i><0.005).</p

Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma - Fig 3

<p>Progression-free survival (A) and overall survival (B) of non-metastatic clear cell renal cell carcinoma patients with and without serum soluble B7-H4.</p

Patient characteristics.

<p>Patient characteristics.</p

Univariate and multivariate analyses of risk factors predicting overall survival in patients with renal cancer.

<p>Univariate and multivariate analyses of risk factors predicting overall survival in patients with renal cancer.</p

Univariate and multivariate analyses of risk factors predicting progression free survival in patients with renal cancer.

<p>Univariate and multivariate analyses of risk factors predicting progression free survival in patients with renal cancer.</p

The association between serum soluble B7-H4 and peripheral blood neutrophils.

<p><b>A:</b> The data were analyzed using the Mann-Whitney U test followed by multiple regression analysis (<i>p</i><0.005). <b>B:</b> The data summarize the findings of 68 RA patients and were analyzed using Spearman's rank test. y = 0.07x−19.6, R² = 0.428, <i>p</i><0.001.</p

Supplementary Methods, Tables S1-S4 from Ribonuclease H2 Subunit A Preserves Genomic Integrity and Promotes Prostate Cancer Progression

Supplementary Table S1. PCR primer sequences for RT-PCR. Supplementary Table S2. Primer sequences for ChIP/DRIP assay. Supplementary Table S3. Relationships of RNASEH2A immunoreactivity (IR) score with clinicopathological findings in prostate cancer (PC) patients. Supplementary Table S4. Univariate and multivariate analysis for recurrence free survival in PC patients.</p

Supplementary Figures S1-S10 from Ribonuclease H2 Subunit A Preserves Genomic Integrity and Promotes Prostate Cancer Progression

Supplementary Figure S1. Loss of RNASEH2A expression repressed CRPC cell growth and migration. Supplementary Figure S2. RNASEH2A inhibits DNA damage response and apoptosis in PC cells.Supplementary Figure S3. siRNASEH2A promotes p53 expression in LNCaP. Supplementary Figure S4. RNASEH2A positively regulates AR expression and downstream signaling. Supplementary Figure S5. RNASEH2A positively regulates AR-mediated cell growth. Supplementary Figure S6. Knockdown of p53 induced AR expression and cell growth. Supplementary Figure S7. DNA methylation is not significantly affected by RNASEH2A knockdown.Supplementary Figure S8. Each RNASEH2 subunit gene expression in PC by using public database. Supplementary Figure S9. The effect of RNase H2 i treatment on LNCaP cells. Supplementary Figure S10. No apparent toxic effect was observed in tissues of mice treated with RNase H2 i.</p

Additional file 3: of Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

Figure S2. Scaled Schoenfeld residuals for each factor. The residual was estimated as the time-dependent coefficient beta (t) vs. transformed time. The proportional hazards assumption of age was violated (p  0.05) (Additional file 2: Table S1). a Age, b Older age, c Sex, d DN, e NS, f CGN, g IgAN, h Other or unknown, i Smoking history, j DM, k Dyslipidemia, l CVD, m IHD, n CHF, o Stroke, p PAD, q RASI, r Statin, s Warfarin, t Antiplatelet agents, u Radiocephalic, v Brachiocephalic (ZIP 1081 kb

Supplementary Table S3 from Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

Mutations, HLA types neoepitopes, and predicted HLA binding</p